Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial

Open access
Ohji, Masahito, Takahashi, Kanji, Okada, Annabelle A., Kobayashi, Masato, Matsuda, Yoshimi, Terano, Yasuhiro, for the ALTAIR Investigators, Ohji, Masahito, Hanemoto, Tsukasa, Kaga, Tatsushi, Kouno, Takeya, Kitamei, Hirokuni, Sato, Shinpei, Takahashi, Kanji, Yanai, Ryoji, Uchio, Eiichi, Miyata, Kazunori, Wakabayashi, Yoshihiro, Maeno, Takatoshi, Yasukawa, Tsutomu, Horiguchi, Masayuki, Nishimura, Tetsuya, Kawahara, Akiteru, Kurimoto, Yasuo, Murai, Kenichi, Kobayashi, Namie, Kimura, Wataru, Matsushita, Eriko, Iida, Tomohiro, Yasuda, Kanako, Kato, Yuji, Miura, Masahiro, Okada, Annabelle Ayame, Mori, Ryusaburo, Sugiyama, Atsushi, Ito, Yasuo, Kimura, Daisaku, Nakai, Kei, Matsumoto, Chota, Takeuchi, Shinobu, Okoshi, Kishiko, Nuno, Yoshihisa, Nomoto, Yohei, Mori, Toshio, Takeda, Muneyasu, Yoshida, Noriko, Hosokawa, Mio, Sonoda, Kohei · 2020 · Advances in Therapy

Abstract

PURPOSE: To evaluate efficacy and safety of intravitreal injections of aflibercept (IVT-AFL) treat-and-extend (T&E) dosing regimens in treatment-naïve patients with exudative age-related macular degeneration (AMD). METHODS: Adults aged at least 50 years old with exudative AMD and best-corrected visual acuity (BCVA) of 73-25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters were included. Patients received three monthly doses of IVT-AFL 2 mg. At week 16, patients were randomized 1:1 to IVT-AFL T&E with either 2- or 4-week adjustments. The primary endpoint was mean change in BCVA from baseline to week 52. Outcomes were assessed at weeks 52 and 96. RESULTS: Baseline characteristics were comparable between the groups (n = 123 each). Over 52 weeks, mean number of injections was 7.2 and 6.9 and mean last injection interval was 10.7 and 11.8 weeks, for the 2- and 4-week groups, respectively. From baseline, mean change in BCVA was + 9.0 and + 8.4 letters (week 52) and + 7.6 and + 6.1 letters (week 96); mean change in central retinal thickness was - 134.4 µm and - 126.1 µm (week 52) and - 130.5 µm and - 125.3 µm (week 96). Last injection interval before week 52 was at least 12 weeks in 42.3% and 49.6% of patients and 56.9% and 60.2% before week 96. Over 96 weeks, mean number of injections was 10.4 (both groups). The safety profile of IVT-AFL was consistent with previous reports. CONCLUSIONS: IVT-AFL administered using two different T&E regimens for treatment-naïve exudative AMD improved functional and anatomic outcomes at week 52 and outcomes were maintained to week 96. Outcomes were similar between the 2- and 4-week groups. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02305238.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-020-01236-x

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 256

Metadata

Authors
Ohji, M., Takahashi, K., Okada, A. A., Kobayashi, M., Matsuda, Y., Terano, Y., for the ALTAIR Investigators, Ohji, M., Hanemoto, T., Kaga, T., Kouno, T., Kitamei, H., Sato, S., Takahashi, K., Yanai, R., Uchio, E., Miyata, K., Wakabayashi, Y., Maeno, T., Yasukawa, T., Horiguchi, M., Nishimura, T., Kawahara, A., Kurimoto, Y., Murai, K., Kobayashi, N., Kimura, W., Matsushita, E., Iida, T., Yasuda, K., Kato, Y., Miura, M., Okada, A. A., Mori, R., Sugiyama, A., Ito, Y., Kimura, D., Nakai, K., Matsumoto, C., Takeuchi, S., Okoshi, K., Nuno, Y., Nomoto, Y., Mori, T., Takeda, M., Yoshida, N., Hosokawa, M., & Sonoda, K.
Venue
Advances in Therapy
Published
2020-02-03
Volume
37
Issue
3
Pages
1173-1187
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W3005138496
Cited by
256
References
24
FWCI
23.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1007/s12325-020-01236-x
The paper
Ohji, M., Takahashi, K., Okada, A. A., Kobayashi, M., Matsuda, Y., Terano, Y., for the ALTAIR Investigators, Ohji, M., Hanemoto, T., Kaga, T., Kouno, T., Kitamei, H., Sato, S., Takahashi, K., Yanai, R., Uchio, E., Miyata, K., Wakabayashi, Y., Maeno, T., . . . Sonoda, K. (2020). Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial. Advances in Therapy. https://doi.org/10.1007/s12325-020-01236-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.